A biopharmaceutical company committed to applying its scientific leadership in cellular metabolism to transform the lives of patients with cancer and rare genetic disorders.  We are growing rapidly with a diverse robust pipeline. We have multiple first-in-class product candidates in late-stage clinical development including AG-221 and AG-120 for AML.  CEO, David Schenkein, formerly of Genentech and Millennium, was voted one of FierceBiotech's Top 25 Most Influential Biopharmaceutical Leaders in 2015.